Fundraising FoxAvedro, Inc. — Full Portfolio
6 tracked investments · listed companies and verified rows first
Glaukos develops micro-scale medical devices and pharmaceuticals for treating glaucoma, corneal disorders, and retinal diseases, replacing traditional drop therapies with minimally invasive surgery platforms.
BiotechHealthtechMedical DevicesAliso Viejo, US
Thomas W. Burns(Chief Executive Officer and Chairman of the Board)
Co-investorsMontreux Equity Partners
iDose TR is a procedural pharmaceutical implant that delivers travoprost therapy to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
BiotechDigital HealthHealthtechMedical Devices
Sophisticated optics for illumination and enhanced visualization in surgical procedures.
HealthtechSan Francisco, US
Kenneth Trauner(Executive Officer, Director)Alex Vayser(Executive Officer)Philip Sawyer(Executive Officer, Director)inTheresa Brandner-Allen(Executive Officer)Brett Robertson(Executive Officer)Doug Rimer(Executive Officer)
Co-investorsAlpine MeridianWindham Capital PartnersHEALTHCARE ROYALTY PARTNERSKleiner PerkinsValence Advantage Life SciencesWellington Management
iDose TR is a treatment for open-angle glaucoma and high eye pressure.
BiotechDigital HealthMedical Devices
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Obalon TherapeuticsRevision Optics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.